Hypothyroidism Treated With Calcitonin

Hypothyroidism Clinical Trial

Official title:

Assessing Quality of Life Changes Using Calcitonin in Patients With Hypothyroidism on Biochemical Replacement With Levothyroxine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03342001
• Other study ID #: HP-00076671
• Status: Completed
• Phase: Phase 4
• Start date: June 18, 2018
• Est. completion date: August 14, 2019

Study information

• Verified date: February 2022
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. We are testing whether giving calcitonin to such people will improve their quality of life.

Description:

It is known that a proportion of patients with hypothyroidism despite serum TSH levels being within the normal reference range, may continue to express symptoms of hypothyroidism. Common symptoms include fatigue, muscle pain, weight gain, and mood changes. Saravanan et al. reported in a large community-based survey that patients on levothyroxine even with a normal TSH showed significant impairment in psychological well-being compared with age- and sex-matched controls. These patients are challenging to manage and are often unhappy with they care.

Established treatment of hypothyroidism is levothyroxine. Thyroid follicular cells synthesize and secrete thyroxine and triiodothyronine. However, even when people are receiving adequate levothyroxine replacement therapy, their quality of life may not improve. Calcitonin (CT) is also produced by the thyroid gland, parafollicular cells. Their levels are not tested in hypothyroidism because the exact role of calcitonin in human health and disease is not fully known. CT has long been thought to play an important role in bone and mineral homeostasis, particularly with respect to its ability to regulate calcium metabolism. CT has been found in fish, reptiles, birds, and mammals. Salmon-derived CT is 50-100 times more potent than human CT. Hence, salmon CT (sCT) has been used for medicinal purposes.

There is a need for further research in order to understand the nature of persisting symptoms in patients on T4 monotherapy despite a serum TSH within the reference range. Calcitonin has been shown to alleviate pain in patients with bone or mineral disorders. To date, the use of calcitonin for relief of hypothyroid symptoms has not been studied.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: August 14, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 88 Years

Eligibility

Inclusion Criteria:

• Normal TSH on levothyroxine therapy

Exclusion Criteria:

1. pregnant or 6 months post partum

2. Current or previous thyroid cancer

3. Congenital hypothyroidism

4. any tobacco use

5. prescribed proton pump inhibitors

6. prescribed steroids

7. taking armour thyroid, naturethroid, or any dessicated thyroid hormone

8. Unstable medical conditions (CKD, Cirrhosis etc)

9. pituitary disease

Related Conditions & MeSH terms

• Hypothyroidism

Intervention

Drug:
• Calcitonin
calcitonin nasal spray

Locations

Country	Name	City	State
United States	University of Maryland Center for Diabetes and Endocrinology	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

References & Publications (1)

Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002 Nov;57(5):577-85. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease	questionnaire to assess quality of life, 40 questions, 1-10 scale with 10 indicating more severe symptoms. Total 400 points, primary assessment was change in score after 6 weeks.	6 weeks